Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amicus Therapeutics (FOLD) Interest Expenses (2016 - 2025)

Amicus Therapeutics' Interest Expenses history spans 16 years, with the latest figure at $11.4 million for Q4 2025.

  • For the quarter ending Q4 2025, Interest Expenses fell 4.43% year-over-year to $11.4 million, compared with a TTM value of $46.2 million through Dec 2025, down 6.93%, and an annual FY2025 reading of $46.2 million, down 6.93% over the prior year.
  • Interest Expenses for Q4 2025 was $11.4 million at Amicus Therapeutics, down from $11.7 million in the prior quarter.
  • The five-year high for Interest Expenses was $13.0 million in Q3 2023, with the low at $8.0 million in Q1 2021.
  • Average Interest Expenses over 5 years is $10.8 million, with a median of $11.5 million recorded in 2025.
  • Year-over-year, Interest Expenses soared 124.21% in 2021 and then decreased 7.89% in 2025.
  • Tracing FOLD's Interest Expenses over 5 years: stood at $8.2 million in 2021, then surged by 35.9% to $11.1 million in 2022, then increased by 15.61% to $12.8 million in 2023, then dropped by 6.77% to $12.0 million in 2024, then dropped by 4.43% to $11.4 million in 2025.
  • Per Business Quant, the three most recent readings for FOLD's Interest Expenses are $11.4 million (Q4 2025), $11.7 million (Q3 2025), and $11.6 million (Q2 2025).